I understand that some of you have written to the company and have received what seemed like robo answers. I also wrote today to complain about communication and to provide some topics that should be okay to discuss. I suggested that they could discuss OHSU and HIV programs, or CCR5 properties, or academic discussions of MABs or other related subjects that might create some buzz. They can always put a disclaimer at the end that Leronlimab is being evaluated for safety concerns etc.
I will evaluate any response. If it sounds like a robo response, I shall demand a proof of life, such as a photo of the respondent standing behind todays edition of The Columbian.
I shall vote no on Tanya.